A pharmacist-led intervention significantly reduced 30-day readmission compared to standard care in African American men with heart failure (11.5% vs. 42.9%; p = .03).
Cohort (n=132)
Does a pharmacist-led intervention reduce 30-day readmission in African American men with heart failure?
A pharmacist-led intervention significantly reduces 30-day readmission rates in African American men hospitalized with heart failure.
Absolute Event Rate: 11.5% vs 42.9%
p-value: p=.03
Heart failure (HF) is responsible for more 30-day readmissions than any other condition. Minorities, particularly African American males (AAM), are at much higher risk for readmission than the general population. In this study, demographic, social, and clinical data were collected from the electronic medical records of 132 AAM patients (control and intervention) admitted with a primary or secondary admission diagnosis of HF. Both groups received guideline-directed therapy for HF. Additionally the intervention group received a pharmacist-led intervention. Data collected from these patients were used to develop and validate a predictive model to evaluate the impact of the pharmacist-led intervention, and identify predictors of readmission in this population. After propensity score matching, the intervention was determined to have a significant impact on readmission, as a significantly smaller proportion of patients in the intervention group were readmitted as compared to the control group (11.5% vs. 42.9%; p = .03). A predictive model for 30-day readmission was developed using K-nearest neighbor (KNN) classification algorithm. The model was able to correctly classify about 71% patients with an AUROC of 0.70. Additionally, the model provided a set of key patient attributes predictive of readmission status. Among these predictive attributes was whether or not a patient received the intervention. A relative risk analysis identified that patients who received the intervention are less likely to be readmitted within 30 days. This study demonstrated the benefit of a pharmacist-led intervention for AAM with HF. Such interventions have the potential to improve quality of life for this patient population.
Mckinley et al. (Wed,) conducted a cohort in Heart failure (n=132). Pharmacist-led intervention vs. Control group (guideline-directed therapy only) was evaluated on 30-day readmission (p=.03). A pharmacist-led intervention significantly reduced 30-day readmission compared to standard care in African American men with heart failure (11.5% vs. 42.9%; p = .03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: